Commentary on 'The DOPPS practice monitor for US dialysis care: Trends through August 2011': An ESA confluence

American Journal of Kidney Diseases

Volumn 60, Issue 1, 2012, Pages 165-167

  Weiner, Daniel E ^a   Winkelmayer, Wolfgang C ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; PARATHYROID HORMONE;

ANEMIA; BONE DISEASE; HEALTH PROGRAM; HUMAN; MEDICAL PRACTICE; MINERAL DEFICIENCY; PATIENT CARE; RENAL REPLACEMENT THERAPY; SHORT SURVEY; STEADY STATE; TREND STUDY;

EID: 84862592341     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2012.04.002     Document Type: Editorial

References (14)

1. Medicare Program; End-Stage Renal Disease Prospective Payment System. 42 CFR Part 410, 413, and 414. [CMS-1418-F] RIN 0938-AP57. Department of Health and Human Services, Centers for Medicare & Medicaid Services, pp 49030-49214.
2. Centers for Medicare & Medicaid Services. Medicare program; end-stage renal disease quality incentive program. Final rule. Fed Regist. 2011;76(3):627-646.
3. Winkelmayer WC, Chertow GM. The 2011 ESRD prospective payment system: an uncontrolled experiment. Am J Kidney Dis. 2011;57(4):542-546.
4. National Committee for Quality Assurance (NCQA). HEDIS & Quality Measurement. Available at: http://www.ncqa.org/tabid/59/Default.aspx. Accessed March 14, 2012.
5. Weiner DE, Miskulin DC. Anemia management in chronic kidney disease: bursting the hemoglobin bubble. Ann Intern Med. 2010;153(1):53-55.
6. US Food and Drug Administration. FDA Drug Safety Communication: modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease. June 24, 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm. Accessed March 16, 2012.
7. Centers for Medicare & Medicaid Services. Medicare program; changes to the end-stage renal disease prospective payment system for CY 2012, end-stage renal disease quality incentive program for PY 2013 and PY 2014; ambulance fee schedule; and durable medical equipment. Fed Regist. 2011;76(131):40498-40550.
8. Robinson B, Fuller D, Zinsser D, et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS) Practice Monitor: rationale and methods for an initiative to monitor the new US bundled dialysis payment system. Am J Kidney Dis. 2011;57(6):822-831.
9. Pisoni RL, Fuller DS, Bieber BA, Gillespie BW, Robinson BM. The DOPPS Practice Monitor for US dialysis care: trends through August 2011. Am J Kidney Dis. 2012;60(1):160-165.
10. Robinson BM, Fuller DS, Bieber BA, Turenne MN, Pisoni RL. The DOPPS Practice Monitor for US dialysis care: trends through April 2011. Am J Kidney Dis. 2012;59(2):309-312.
11. Winkelmayer WC, Weiner DE. Commentary on 'the DOPPS Practice Monitor for US dialysis care: trends through April 2011': no surprises yet. Am J Kidney Dis. 2012;59(2):312-314.
12. Joly D, Drueke TB, Alberti C, et al.Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis. 2008;51(6):987-995.
13. Ibrahim HN, Ishani A, Foley RN, Guo H, Liu J, Collins AJ. Temporal trends in red blood transfusion among US dialysis patients, 1992-2005. Am J Kidney Dis. 2008;52(6):1115-1121.
14. Ibrahim HN, Skeans MA, Li Q, Ishani A, Snyder JJ. Blood transfusions in kidney transplant candidates are common and associated with adverse outcomes. Clin Transplant. 2011;25(4):653-659.